[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"angina\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:angina":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100499681","phase-4-livebetter-a-trial-comparing-medications-in-older-adults-with-stable-angina-and-multiple-chronic-conditions-100499681",false,"NCT05786417","LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions","A Trial Comparing the Effectiveness and Tolerability of Medications in Older Adults With Stable Angina and Multiple Chronic Conditions: LIVEBETTER","LIVEBETTER","Inclusion Criteria:\n\nOLDER ADULTS WITH SIHD AND MCC\n\n* Age ≥65 years\n* ≥ 2 Multiple Chronic Conditions as defined by Centers for Medicare and Medicaid Services (CMS)\n* Diagnosis of Symptomatic Stable Ischemic Heart Disease with plans to initiate medical therapy identified by at least one of the following:\n\n  1. positive non-invasive functional or anatomic testing suggestive of obstructive coronary artery disease\n  2. coronary angiography with stenosis ≥70% in a coronary artery ≥2 mm in diameter or\n\n     ≥50% stenosis of left main\n  3. Invasive coronary angiography with positive physiologic testing in at least one vessel (FFR ≤ 0.80 or iFR ≤0.89)\n\nCAREGIVERS\n\n* Age ≥ 18 years\n* Identified as caregiver of LIVEBETTER participant\n\nExclusion Criteria:\n\nOLDER ADULTS WITH SIHD AND MCC\n\n* Current taking (both) a beta-blocker AND a calcium channel blocker\\*\n* Contraindication to beta-blockers or calcium channel blockers including:\n\n  1. significant hypotension\n  2. high grade AV block\n  3. severe symptomatic bradycardia\n  4. severe obstructive lung disease\n* Documented intolerance to beta-blockers or calcium channel blockers\n* Probable or definite high-risk coronary artery disease including unrevascularized left main disease and\u002For unrevascularized multi-vessel disease including the proximal left anterior descending (LAD) artery with plans for immediate complete revascularization\n* Plans for complete revascularization within 2 weeks\n* Clear clinical indication for beta-blockers or calcium channel blockers that precludes dose adjustment or crossover:\n\n  1. Diagnosis of acute coronary syndrome (ACS) with reduced ejection fraction within past year\n  2. Heart failure with reduced ejection fraction (HFrEF) within past year\n* Actively participating in another clinical trial involving an investigational medication or device\n* Primary language other than English or Spanish\n* Inability to complete follow-up (e.g. life expectancy \\\u003C12 months, impaired decision-making determined by validated instrument)\n* Previously enrolled in LIVEBETTER\n* Refused informed consent\n\nCAREGIVERS\n\n* Professional caregiver (i.e. not a relative or close friend of the participant)\n* Primary language other than English or Spanish\n* Inability to complete follow-up\n* Previously enrolled in LIVEBETTER\n* Refused informed consent","ALL","65 Years",{"count":20,"type":21},741,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","To establish the effectiveness and tolerability of standard of care anti-anginal treatment (beta-blocker and calcium channel blocker medications) in older adults with symptomatic Stable Ischemic Heart Disease (SIHD) and multiple chronic conditions (MCC).",[27,28],"Angina","Stable Ischemic Heart Disease","RECRUITING","2026-04-06",{"date":32,"type":33},"2026-04-07","ACTUAL",{"date":35,"type":33},"2023-05-10",{"date":37,"type":21},"2027-05-30",{"name":39,"class":40},"Yale University","OTHER",10,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":66,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100620566","impact-of-a-multimodal-intervention-on-antibiotic-prescribing-for-respiratory-infections-in-primary-care-100620566","NCT07359287","Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care","Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care: A Cluster-Randomized Trial","GRASP","Inclusion Criteria:\n\n\\- Patient seen in consultation for an upper or lower respiratory tract infection (Angina, Acute bronchiolitis, Acute bronchitis, COPD exacerbation (AECOPD), Laryngitis, Acute otitis media (AOM), Serous or congestive otitis, Viral respiratory infection (e.g., influenza), Community-acquired pneumonia (CAP), Rhinitis \u002F Nasopharyngitis, Acute sinusitis)\n\nExclusion Criteria:\n\n\\- Patient under legal protection",{"count":51,"type":21},4500,[53],"NA","Antimicrobial resistance (AMR), considered one of the greatest global threats by the WHO, justifies the development of initiatives to promote appropriate antibiotic use-especially in primary care, where most antibiotics in France are prescribed and where misuse remains common.\n\nWe are proposing a cluster-randomized controlled trial to evaluate the effectiveness of a bimodal intervention combining: (1) improved communication about the circulation of respiratory viruses, and (2) strengthened collaborative practices between general practitioners and pharmacists through a multidisciplinary protocol aimed at verifying that prescribed treatment durations comply with guidelines.\n\nThe study will include six primary care practices (24 physicians), with three practices in each study arm.\n\nThe aim of this project is to assess whether the bimodal intervention can reduce the duration of antibiotic treatments for upper and lower respiratory tract infections. The first component (a \"viral infection prescription\" tool) focuses on reducing unnecessary treatment initiation, while the second (pharmacist-led review) aims to shorten excessive prescription durations.",[27,56,57,58,59,60,61,62,63,64,65],"Acute Bronchiolitis","Acute Bronchitis","COPD Exacerbation (AECOPD)","Laryngitis","Acute Otitis Media (AOM)","Serous or Congestive Otitis","Viral Respiratory Infection (e.g., Influenza)","Community-Acquired Pneumonia (CAP)","Rhinitis \u002F Nasopharyngitis","Acute Sinusitis",[67,68],"Upper respiratory tract infection","Lower respiratory tract infection","2026-01-13",{"date":71,"type":33},"2026-01-22",{"date":73,"type":33},"2025-12-01",{"date":75,"type":21},"2026-09-01",{"name":77,"class":40},"University Hospital, Caen",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":78},"100487970","imaging-coronary-microvascular-dysfunction-cmd-study-100487970","NCT05634031","Imaging Coronary Microvascular Dysfunction (CMD) Study","Development and Validation of a Non-invasive Algorithm for Diagnosis of Microvascular Angina Among Patients With Ischemia and Non-obstructive Coronary Artery Disease (IMAGING-CMD Study)","Inclusion criteria:\n\n* Patients with symptoms of exertional angina and\u002For dyspnea (confirmed on Seattle Angina Questionnaire and Rose Dyspnea Questionnaire)\n* Evidence of non-obstructive CAD on CCTA or coronary angiography (no stenosis \\>50% and\u002For FFR if performed \\>0.80)\n\nExclusion criteria:\n\n* Patients with reduced LVEF (\\\u003C50%) or diagnosis of cardiomyopathy\n* Patients with co-existent moderate or severe valve disease\n* Patients with eGFR \\\u003C30 ml\u002Fmin\u002Fm2\n* History of prior coronary revascularization\n* Non-coronary indication for CCTA or coronary angiogram determining eligibility\n* Contraindications to regadenoson (severe asthma\u002Fchronic obstructive pulmonary disease, brady-arrhythmias, or systolic blood pressure \\\u003C90 mm Hg)\n* Inability to provide informed consent\n* Pregnancy","18 Years",{"count":88,"type":21},70,[53],"Angina is a common clinical symptom of ischemic heart disease, affecting up to 11 million people in the United States alone, and 112 million people globally. Despite this, 4 in 10 patients undergoing elective coronary angiography for angina and ischemia do not have evidence of obstructive coronary artery disease (CAD). This condition of ischemia with no obstructive CAD (INOCA) is associated with high clinical and economic morbidity, as these patients have a higher rate of repeat procedures and hospitalizations, worse quality of life, future adverse cardiovascular events and frequent time missed from work.\n\nThe overall objective of this study is to develop and validate a non-invasive algorithm for diagnosis and management of patients with INOCA and suspected microvascular dysfunction centered around cardiac PET MPI. A secondary goal of the study is to assess for improvement in patient symptoms, function and quality of life from PET-guided management of CMD in patients with INOCA.\n\nThis study will take place at Mount Sinai Morningside in the PET and CTunit on the 3rd floor. The sub-study will occur at Mount Sinai Morningside Cath Lab on the 3rd floor. The study will enroll an estimated total of 70 subjects, 12 of which will also participate in the sub-study. The study is estimated to last 2 years.",[27,92],"Non-obstructive Coronary Artery Disease","2025-04-11",{"date":95,"type":33},"2025-04-16",{"date":97,"type":33},"2023-04-26",{"date":99,"type":21},"2027-03-01",{"name":101,"class":40},"Icahn School of Medicine at Mount Sinai"]